Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancer Risk Syndrome”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02206360
What this trial is testing

Pancreatic Cancer Early Detection Program

Who this might be right for
Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma+8 more
White Plains Hospital 181
Testing effectiveness (Phase 2)Looking for participantsNCT04068597
What this trial is testing

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Who this might be right for
Haematological MalignancyAcute Myeloid LeukemiaNon Hodgkin Lymphoma+3 more
CellCentric Ltd. 250
Early research (Phase 1)WithdrawnNCT05823480
What this trial is testing

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center
Early research (Phase 1)Study completedNCT02052908
What this trial is testing

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

Who this might be right for
Lynch Syndrome
National Cancer Institute (NCI) 81
Testing effectiveness (Phase 2)Study completedNCT03338348
What this trial is testing

Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
University of Ulm 9
Not applicableEnrolling By InvitationNCT07072676
What this trial is testing

The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.

Who this might be right for
Inclusion Body MyositisMyotonic Dystrophy 1Myotonic Dystrophy 2+10 more
LMU Klinikum 30
Testing effectiveness (Phase 2)Study completedNCT00290992
What this trial is testing

Rasburicase for Hyperuricemia

Who this might be right for
Nutritional and Metabolic Diseases
Sanofi 30
Testing effectiveness (Phase 2)Study completedNCT00778375
What this trial is testing

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
M.D. Anderson Cancer Center 122
Early research (Phase 1)Ended earlyNCT00589316
What this trial is testing

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+7 more
Fred Hutchinson Cancer Center
Large-scale testing (Phase 3)Study completedNCT03092674
What this trial is testing

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeMyelodysplastic Syndrome/Acute Myeloid Leukemia
National Cancer Institute (NCI) 76
Testing effectiveness (Phase 2)Looking for participantsNCT06046313
What this trial is testing

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
First Affiliated Hospital of Zhejiang University 120
Not applicableStudy completedNCT00001120
What this trial is testing

Patients With AIDS Syndrome

Who this might be right for
Sarcoma, KaposiLymphoma, Non-HodgkinHIV Infections+1 more
National Institute of Allergy and Infectious Diseases (NIAID) 5,000
Early research (Phase 1)Ended earlyNCT00003926
What this trial is testing

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsChildhood Germ Cell TumorChordoma+6 more
Masonic Cancer Center, University of Minnesota 13
Testing effectiveness (Phase 2)Ended earlyNCT04849910
What this trial is testing

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Vor Biopharma 67
Testing effectiveness (Phase 2)WithdrawnNCT02765997
What this trial is testing

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Myelogenous Leukemia+1 more
Masonic Cancer Center, University of Minnesota
Early research (Phase 1)Ended earlyNCT02841540
What this trial is testing

H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Hemavant Sciences GmbH 127
Not applicableActive Not RecruitingNCT05759143
What this trial is testing

Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing

Who this might be right for
Genetic Predisposition to DiseaseGenetic Predisposition
Dana-Farber Cancer Institute 40
Early research (Phase 1)Looking for participantsNCT04243785
What this trial is testing

BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Edgewood Oncology Inc. 80
Early research (Phase 1)Looking for participantsNCT03113643
What this trial is testing

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 72
Testing effectiveness (Phase 2)WithdrawnNCT02829840
What this trial is testing

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Who this might be right for
LeukemiaFLT3-Mutated Acute Myeloid LeukemiaFLT3-Mutated High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Next Page
26